Concepedia

Daniel E. Stepan

DE

Statistics

Publications

21

Citations

3.8K

H-Index

18

Active since

1981

Affiliations

Oregon Health & Science University(Current)

Eisai (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

South Texas Accelerated Research Therapeutics

Memorial Sloan Kettering Cancer Center

Daniel E. Stepan is an author at Oregon Health & Science University specializing in medicine, oncology, and pharmacology.

Publications per year

1981–2020

21

Publications

21

Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation

J.-A. H. van Burik, V. Ratanatharathorn, Daniel E. Stepan et al. · Clinical Infectious Diseases · 2004 · 742 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker, Matthew H. Taylor, Carol Aghajanian et al. · Journal of Clinical Oncology · 2020 · 522 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Vicky Makker, Drew Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2019 · 480 citations · Full text

Medicine, Oncology, Pharmacology +6

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Steven I. Sherman, Lori J. Wirth, Jean-Pierre Droz et al. · New England Journal of Medicine · 2008 · 471 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

Matthew H. Taylor, Chung‐Han Lee, Vicky Makker et al. · Journal of Clinical Oncology · 2020 · 456 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 21